171 related articles for article (PubMed ID: 22542448)
1. Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.
Foss F; Horwitz SM; Coiffier B; Bartlett N; Popplewell L; Pro B; Pinter-Brown LC; Shustov A; Furman RR; Haioun C; Koutsoukos T; O'Connor OA
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):238-43. PubMed ID: 22542448
[TBL] [Abstract][Full Text] [Related]
2. Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides.
Talpur R; Thompson A; Gangar P; Duvic M
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):297-304. PubMed ID: 24589156
[TBL] [Abstract][Full Text] [Related]
3. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
O'Connor OA; Pro B; Pinter-Brown L; Bartlett N; Popplewell L; Coiffier B; Lechowicz MJ; Savage KJ; Shustov AR; Gisselbrecht C; Jacobsen E; Zinzani PL; Furman R; Goy A; Haioun C; Crump M; Zain JM; Hsi E; Boyd A; Horwitz S
J Clin Oncol; 2011 Mar; 29(9):1182-9. PubMed ID: 21245435
[TBL] [Abstract][Full Text] [Related]
4. Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma.
Shimanovsky A; Dasanu CA
Expert Opin Pharmacother; 2013 Mar; 14(4):515-23. PubMed ID: 23409799
[TBL] [Abstract][Full Text] [Related]
5. Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial.
Azzoli CG; Patel JD; Krug LM; Miller V; James L; Kris MG; Ginsberg M; Subzwari S; Tyson L; Dunne M; May J; Huntington M; Saunders M; Sirotnak FM
J Thorac Oncol; 2011 Nov; 6(11):1915-22. PubMed ID: 21841501
[TBL] [Abstract][Full Text] [Related]
6. Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma.
Duvic M; Kim YH; Zinzani PL; Horwitz SM
Clin Cancer Res; 2017 Jul; 23(14):3552-3556. PubMed ID: 28167509
[No Abstract] [Full Text] [Related]
7. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
Amengual JE; Lichtenstein R; Lue J; Sawas A; Deng C; Lichtenstein E; Khan K; Atkins L; Rada A; Kim HA; Chiuzan C; Kalac M; Marchi E; Falchi L; Francescone MA; Schwartz L; Cremers S; O'Connor OA
Blood; 2018 Jan; 131(4):397-407. PubMed ID: 29141948
[TBL] [Abstract][Full Text] [Related]
8. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.
Horwitz SM; Kim YH; Foss F; Zain JM; Myskowski PL; Lechowicz MJ; Fisher DC; Shustov AR; Bartlett NL; Delioukina ML; Koutsoukos T; Saunders ME; O'Connor OA; Duvic M
Blood; 2012 May; 119(18):4115-22. PubMed ID: 22394596
[TBL] [Abstract][Full Text] [Related]
9. Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis.
Hong JY; Yoon DH; Yoon SE; Kim SJ; Lee HS; Eom HS; Lee HW; Shin DY; Koh Y; Yoon SS; Jo JC; Kim JS; Kim SJ; Cho SH; Lee WS; Won JH; Kim WS; Suh C
Sci Rep; 2019 Dec; 9(1):20302. PubMed ID: 31889144
[TBL] [Abstract][Full Text] [Related]
10. Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study.
Hong X; Song Y; Huang H; Bai B; Zhang H; Ke X; Shi Y; Zhu J; Lu G; Liebscher S; Cai C
Target Oncol; 2019 Apr; 14(2):149-158. PubMed ID: 30904980
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma.
Foss FM
Expert Opin Drug Metab Toxicol; 2011 Sep; 7(9):1141-52. PubMed ID: 21726160
[TBL] [Abstract][Full Text] [Related]
12. Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.
Parker T; Barbarotta L; Foss F
Future Oncol; 2013 Jan; 9(1):21-9. PubMed ID: 23252560
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma.
Maruyama D; Nagai H; Maeda Y; Nakane T; Shimoyama T; Nakazato T; Sakai R; Ishikawa T; Izutsu K; Ueda R; Tobinai K
Cancer Sci; 2017 Oct; 108(10):2061-2068. PubMed ID: 28771889
[TBL] [Abstract][Full Text] [Related]
14. A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
Dunn TJ; Dinner S; Price E; Coutré SE; Gotlib J; Hao Y; Berube C; Medeiros BC; Liedtke M
Br J Haematol; 2016 Apr; 173(2):253-9. PubMed ID: 27040320
[TBL] [Abstract][Full Text] [Related]
15. Pralatrexate for refractory mycosis fungoides in two Japanese patients.
Teraishi M; Oguro T; Kusume E; Kobashi H; Sano H; Fujioka A; Yamamoto M; Nakajima H; Sano S
J Dermatol; 2021 May; 48(5):667-671. PubMed ID: 33454985
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment.
Kelly KR; Gabrail N; Weitman S; Sarantopoulos J; Olszanski AJ; Edenfield W; Venitz J; Reddy G; Yang A; Hasal SJ; Lockhart AC
Cancer Chemother Pharmacol; 2016 Nov; 78(5):929-939. PubMed ID: 27638045
[TBL] [Abstract][Full Text] [Related]
17. Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.
Hui J; Przespo E; Elefante A
J Oncol Pharm Pract; 2012 Jun; 18(2):275-83. PubMed ID: 21956523
[TBL] [Abstract][Full Text] [Related]
18. Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy.
Koch E; Story SK; Geskin LJ
Leuk Lymphoma; 2013 Nov; 54(11):2448-51. PubMed ID: 23442065
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.
Azzoli CG; Krug LM; Gomez J; Miller VA; Kris MG; Ginsberg MS; Henry R; Jones J; Tyson L; Dunne M; Pizzo B; Farmer A; Venkatraman E; Steffen R; Sirotnak FM
Clin Cancer Res; 2007 May; 13(9):2692-8. PubMed ID: 17473201
[TBL] [Abstract][Full Text] [Related]
20. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.
O'Connor OA; Horwitz S; Hamlin P; Portlock C; Moskowitz CH; Sarasohn D; Neylon E; Mastrella J; Hamelers R; Macgregor-Cortelli B; Patterson M; Seshan VE; Sirotnak F; Fleisher M; Mould DR; Saunders M; Zelenetz AD
J Clin Oncol; 2009 Sep; 27(26):4357-64. PubMed ID: 19652067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
